Clinical trials: Chimeric Antigen Receptor T-cell Therapy, open to volunteers
- Condition Chimeric Antigen Receptor T-cell Therapy
- Status Open to volunteers
- Accepts healthy volunteers yes
Leukemia, Hematopoetic Stem Cell Transplantation
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a…
- Conditions
- Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy
- Trial name
- Allo-X (NCT06643221)
- Testing
- Exercise, Isoproterenol, Bisoprolol Fumarate Tablet 10 mg
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Arizona
HIV-1
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
Human immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS).
- Trial name
- NCT06252402
- Testing
- CMV/HIV-CAR T Cells
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Hematologic Malignancies
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
The overall purpose of this randomized control trial (RCT) is to determine the clinical effect of a multilevel, RPM-enhanced intervention during and after completion of outpatient CAR-T therapy in 190 patients and their family…
- Trial name
- NCT07186192
- Testing
- Educational Intervention, Health Telemonitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Diffuse Large B Cell Lymphoma
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment.
- Trial name
- CARTROG (NCT06352242)
- Testing
- Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients, Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers
- Where
- 2 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Non Small Cell Lung Cancer
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
This study is a single arm, open-label, intravenous infusion of Anti- Epidermal growth factor receptor (EGFR) Chimeric Antigen Receptor (CAR) T cells modified by C-X-C Chemokine receptor type 5 (CXCR 5) in patients with advanced…
- Trial name
- NCT05060796
- Testing
- CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells
- Where
- China
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Relapsed/Refractory Small Cell Lung Cancer
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
This is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants.
- Trial name
- NCT07249879
- Testing
- GC511B CAR-T Cell Injection
- Where
- 2 sites in China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497361
- Testing
- PRG-2311
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Lymphoma, Leukemia
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells.
- Trial name
- NCT05237986
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Non Hodgkin Lymphoma
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
This is a phase I/Ib imaging study of granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64Cu-GRIP B) Positron Emission Tomography (PET) in patients with relapsed/refractory…
- Trial name
- NCT06522932
- Testing
- 64Cu-GRIP B, Positron Emission Tomography (PET), Optional tumor biopsy
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Michael Randall